Table 3.

Effect of BMI on immune reconstitution outcome of CD4 more than 500cells/μL during the follow-up after antiretroviral therapy

Covariate	HR (95% CI)	p	Adjusted HR (95% CI)	p
Continuous BMI	1.06 (1.03 to 1.08)	< 0.01	1.03 (1.01 to 1.06)	0.011
Sex (female vs male)	0.78 (0.56 to 1.07)	0.118	–	–
Age	0.98 (0.97 to 0.98)	< 0.01	0.99 (0.98 to 1.00)	0.004
Baseline CD4 (per 100cells/μL increase)
1–100	Ref		Ref
101–200	3.03 (1.95 to 4.70)	< 0.01	2.92 (1.78 to 4.78)	< 0.01
201–300	10.36 (6.91 to 15.52)	< 0.01	10.38 (6.40 to 16.82)	< 0.01
301–400	25.82 (17.12 to 38.93)	< 0.01	25.42 (15.48 to 41.75)	< 0.01
401–499	56.37 (36.40 to 87.30)	< 0.01	52.06 (30.75 to 88.13)	< 0.01
CD4/CD8 ratio	16.07 (11.67 to 22.12)	< 0.01	2.47 (1.47 to 4.13)	0.001
Baseline viral load (per log10 increase) (copies/mL)
≤ 3.00	Ref		Ref
≥ 6.01	0.53 (0.23 to 1.25)	0.147	4.60 (1.90 to 11.16)	0.001
5.01–6.00	0.83 (0.44 to 1.57)	0.569	2.62 (1.37 to 4.99)	0.004
4.01–5.00	1.22 (0.65 to 2.28)	0.540	1.97 (1.05 to 3.72)	0.035
3.01–4.00	1.53 (0.80 to 2.92)	0.201	1.68 (0.87 to 3.22)	0.120
WHO stage
I	Ref		Ref
II	0.41 (0.27 to 0.63)	< 0.01	0.62 (0.40 to 0.97)	0.037
III	0.34 (0.23 to 0.51)	< 0.01	0.67 (0.44 to 1.04)	0.074
IV	0.22 (0.14 to 0.33)	< 0.01	1.09 (0.68 to 1.75)	0.736
Drinking (yes vs no)	1.04 (0.90 to 1.20)	0.593	–	–
Race (not Han vs Han)	0.98 (0.79 to 1.21)	0.834	–	–

CI confidence intervals, HR hazard ratios, Ref reference